Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA clears IND for phase I/II study of PBKR-03 for Krabbe disease

Feb. 8, 2021

PCOS passed on in the epigenes

Feb. 8, 2021

Crinetics' lead candidate CRN-04894 enters phase I development

Feb. 5, 2021

"Inceptor" is new diabetes target

Feb. 5, 2021

ViaCyte begins phase II study of VC01-103 in type 1 diabetes

Feb. 4, 2021

Crinetics initiates phase I study of CRN-04777

Feb. 4, 2021

Immunovant pauses dosing in trials of IMVT-1401

Feb. 2, 2021

Prothena plans phase III study of birtamimab for patients with Mayo stage IV AL amyloidosis

Feb. 2, 2021

FDA lifts clinical hold on ACTION-Galactosemia Kids pediatric study of AT-007

Feb. 1, 2021

Topline results from ENHANCE-IT study of Lypdiso in hypertriglyceridemia

Feb. 1, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...